ERR2598293
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 21
- umap1_2d
- -4.853358386
- umap2_2d
- -3.164843127
- umap1_3d
- 3.368997598
- umap2_3d
- 1.762119551
- umap3_3d
- -0.650888222
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.330
- MYOGENESIS+0.290
- KRAS_SIGNALING_DN+0.250
- INTERFERON_GAMMA_RESPONSE+0.190
- XENOBIOTIC_METABOLISM+0.160
- COAGULATION+0.120
- ALLOGRAFT_REJECTION+0.080
- BILE_ACID_METABOLISM+0.080
- PANCREAS_BETA_CELLS+0.040
- ADIPOGENESIS+0.030
Top 10 suppressed
- MYC_TARGETS_V1-0.580
- MYC_TARGETS_V2-0.520
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.460
- MTORC1_SIGNALING-0.460
- TGF_BETA_SIGNALING-0.420
- ANGIOGENESIS-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O1-A52J-01A-11R-A262-07 | — | cohortA1 | 0.900 |
| 2 | MDT-AP-0810 | Med | Medulloblastoma | 0.870 |
| 3 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.866 |
| 4 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.862 |
| 5 | MDT-AP-2296 | Med | Medulloblastoma | 0.845 |
| 6 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.843 |
| 7 | TCGA-CV-7238-01A-11R-2016-07 | — | — | 0.842 |
| 8 | ERR2598273 | fetal | fetal | 0.840 |
| 9 | ERR2598332 | fetal | fetal | 0.840 |
| 10 | MNG882 | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |